Management of Telemedicine Monitoring of Patients With Chronic Heart Failure

Sponsor
Trnava University in Trnava (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05885425
Collaborator
(none)
200
12

Study Details

Study Description

Brief Summary

Objective: to evaluate the possibilities and effect of telemedicine monitoring and management of patients with CHF (compared to patients with CHF without intensive telemedicine monitoring) on quality of life, prognosis and the presence of complications and hospitalisations.

Patients with a stable form of congestive heart failure will be gradually included in the study. Half of them will be defined by random selection to intervention group. Parameters, that can be measured at home will be periodically telemedical monitored. In according with at home monitored data, the own physician will be able to intervene with change of medical treatment in the case of non-physiological deviations in order to improve the health status as well as the prognosis of the patient with CHF.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Telemedicine correction of medical treatment
  • Behavioral: Education for proper lifestyle

Detailed Description

Inclusion criteria:
  • Age between 45 and 75

  • Congestive heart failure (CHF), NYHA II - VI (any genesis)

  • EF less then 45%, any rhythm (sinus or atrial fibrillation)

  • More as two months stable condition

  • Complete treatment according to recommendations (guidelines): ACEI (alternatively ARNI / sartan) + diuretics + betablockers (as alternative digitalis)

  • Without hospitalization with CHF decompensation more as two months before enrolment

  • No severe liver disease and hemodialysis treatment

  • No planned any cardio-surgery intervention in the next six months

  • No a serious valvular defects

Input and output surveys (measurements, tests) upon enrollment and after half a year ECHOCG (mandatory parameters: EF, LVDd, IVCT, E/A, LA diameter, LA area planimetrically) Blod pressure, frequency, ECG (PQ, QT, description: blockages, STT segment changes) Six minutes walking test Serum analysis: NTproBNP, CRP, natrium, potassium, urea, creatinine

Questionnaires:
  • Kansas Quality of Life Questionnaire (KCCQ)

  • Questionnaire SF 36 (perception of illness)

  • Beck's Depression Inventory (21 questions) - depression questionnaire

  • Beck's Anxiety Inventory (21 questions) - anxiety questionnaire (standardized questionnaires translated into Slovak)

Telemedicine monitoring: the patient will have at home devices for:

ECG recording Blood pressure and pulse sensor O2 saturation sensor Personal weight machine

Data will be transferred via smartphone software (supplied by the organizer) once a week too physician:

ECG recording on the patient's instructions

  1. st morning in bed after waking up (stick electrodes for whole day)

  2. nd. after breakfast (or an hour after getting out of bed)

  3. th. around 12 o'clock (time of lunch)

In the same day morning, weight and other measurements (O2, blood pressure, pulse)

As part of the data transfer, the information for physician:

possibility to send a comment "how I feel" the number of urinations per night Data is entered into a standard table in the doctor's software (supplied by the organizer) Based on the obtained data, the doctor can correct the treatment at any time by telephone

Physician will control the transferred data from patient at least once every week.

The organizer will deliver Personal weight machine (new uniform) Questionnaires (in printed form) Informed consents devices for monitoring of physiological functions (ECG, O2, pulse, blood pressure) Application for the patient's smartphone (for simple data transfer) Software recording data from the patient to the PC at the physician's office Compensation 100,- € (motivation for each participant - intervened or non-intervened) similar compensation is assumed at the end of follow-up (for each patient) The ECG sensor will remain available to the physicians Included doctors will be co-authors of publications in foreign journals.

Monitored events ("end points"):

hospitalization for cardiac causes visit to the emergency room (urgent) calling Quick Medical Assistance at home unplanned visit by cardiologist / internist fundamental change of treatment (new type of drug, change of drug group, increased dose) fundamental changes (deterioration) in the perception of the disease (SF 36) major changes in quality of life (Kansas Questionnaire) fundamental changes in the perception of depression (Beck's Depression Inventory) fundamental changes in the perception of anxiety (Beck's Anxiety Inventory) Death

Evaluation in addition to endpoints:

long-term trend of resting frequency long-term trend of increased frequency after morning exercise and during the day long-term blood pressure and saturation trends number of telephone contacts by physicians with the patient in the case of using a "smart watch", also trends in sleep parameters (frequency, apnea, sleep quality, caloric expenditure / day)

Study Design

Study Type:
Observational
Anticipated Enrollment :
200 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
TELEHEART-Management of Telemedicine Monitoring of Patients With Chronic Heart Failure
Anticipated Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
May 1, 2024
Anticipated Study Completion Date :
Sep 1, 2024

Arms and Interventions

Arm Intervention/Treatment
100 patients with stabile chronic heart failure with remote control

Group 1 is the intervention group, their health status will be monitored telemetrically for a half year by several electronic devices (for measurement of hearth frequency, blood pressure, blood saturation and periodically ECG recordings). Data will be periodically transmitted to the doctor in the ambulance. If measured data will indicated any worsening of heath (decompensation of circulation), physician will adjust the treatment remotely.

Behavioral: Telemedicine correction of medical treatment
On the basis of telemedicine data, the doctor will remotely correct medical treatment by adjusting the dose or supplementing or by omitting the medicine in order to improve the state of health, or to alleviate the symptoms of the disease monitored by telemedicine

Behavioral: Education for proper lifestyle
Based on telemedicine data, the doctor can consider periodic education of the patient with the innervated group in order to improve lifestyle

Non-intervention group: 100 patients with stabile chronic heart failure without remote control

Group 2 with patients with chronic heart failure in the non-intervention group, they will not be contacted by own physician for half a year - the planned periodic control will be scheduled after half a year.

Outcome Measures

Primary Outcome Measures

  1. Hospitalization for cardiac reasons [6 months]

  2. Visit to the emergency room (urgent) [6 months]

Secondary Outcome Measures

  1. Unplanned visit to cardiology / internist [6 months]

  2. Calling Quick Medical Assistance home [6 months]

  3. Fundamental change of treatment (new type of drug, change of drug group, increased dose) [6 months]

  4. Fundamental changes in the quality of life according to questionnaires [6 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
45 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Congestive heart failure (CHF), NYHA II - VI (any genesis)

  • EF less then 45%, any rhythm (sinus or atrial fibrillation)

  • More as two months stable condition

  • Complete treatment according to recommendations (guidelines): ACEI (alternatively ARNI / sartan) + diuretics + betablockers (as alternative digitalis)

  • Without hospitalization with CHF decompensation more as two months before enrolment

Exclusion Criteria:
  • malignant diseases

  • planned cardiac surgery

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Trnava University in Trnava

Investigators

  • Principal Investigator: Eva Goncalvesova, National Institute of Vascular and Heart Diseases Bratislava
  • Study Chair: Fedor Lehocki, Slovak University of Technology in Bratislava
  • Study Director: Jozef Benacka, Trnava University in Trnava

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Trnava University in Trnava
ClinicalTrials.gov Identifier:
NCT05885425
Other Study ID Numbers:
  • OPII-VA/DP/2021/9.3-01
First Posted:
Jun 2, 2023
Last Update Posted:
Jun 2, 2023
Last Verified:
May 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Trnava University in Trnava
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 2, 2023